Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ACINETWORK

Financiado

Cerrado

A training network for the design of synthetic carbohydrate-based vaccines in th...

A training network for the design of synthetic carbohydrate-based vaccines in the fight against multi-drug resistant nosocomial pathogen Acinetobacter baumannii Bacterial infections are a societal burden with profound medical and socio-economic impacts. Although antibiotics can be effective, the continuous emergence of bacteria with antimicrobial resistance calls for the introduction of n... ver más

31/01/2028

UMIL

Presupuesto desconocido

Líder del proyecto

UNIVERSITA DEGLI STUDI DI MILANO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-01

HORIZON-MSCA-2022-DN-01-01: MSCA Doctoral Networks 2022 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

UMIL

Lider

Proyectos interesantes

SV-STAPH-VAX

Medical Technol...

Data Science

187K€ Cerrado

INBIONET

Medical Technol...

Data Science

4M€ Cerrado

RTI2018-099985-B-I00

Medical Technol...

Data Science

151K€ Cerrado

BactiVax

Medical Technol...

Data Science

4M€ Cerrado

RTC-2016-5161-1

Medical Technol...

Pharmaceutical...

213K€ Cerrado

IN-ARMOR

Medical Technol...

Data Science

6M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 47 meses Fecha Inicio: 2024-02-01
Fecha Fin: 2028-01-31

Líder del proyecto

UNIVERSITA DEGLI STUDI DI MILANO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Bacterial infections are a societal burden with profound medical and socio-economic impacts. Although antibiotics can be effective, the continuous emergence of bacteria with antimicrobial resistance calls for the introduction of novel therapeutics. In this regard, glycoconjugate vaccines (GV) hold a prominent role in the fight against AMR bacterial strains. They are based on the chemical conjugation of one or more pathogen-associated saccharide antigens to immunogenic carriers, leading to a long-term protective immunity. ACINETWORK will focus on the development of GV against severe and life-threatening infections caused by antimicrobial resistant Acinetobacter baumannii strains, which are a major cause of nosocomial diseases and for which no vaccine exists. ACINETWORK wants to overcome the limitations of currently licensed GV, due to highly heterogeneous composition and batch wise variability, by innovatively using structurally-defined synthetic oligosaccharide antigens to develop GV with well-defined composition, higher purity and better safety profiles. The manufacturing of such GV is also more rapid and cost-effective. Thus, this project will set synthesis and testing pipelines that will serve as the prototype for the development of GV against other bacteria. The ACINETWORK consortium comprises universities and SMEs with a unique complementary expertise, ranging from carbohydrate chemistry to nanotechnology, immunology and microbiology, which garantees the realization of the new GV. The goal of ACINETWORK is to also forge 10 young experts in the design of these novel medical solutions with an integrated training program, which will equip them with a large battery of scientific and transferable skills. The multidisciplinarity of the consortium ensures a fertile and stimulating environment in which these young researchers will acquire unique competencies in vaccine design, development and production, which will be central at putting Europe at the forefront of GV.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores